Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling

Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling

Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling

[vc_row][vc_column][vc_column_text]

Abstract/ Significance:

Glioblastoma (GBM) is a prevalent and highly lethal form of glioma, with rapid tumor progression and frequent recurrence. Excessive outgrowth of pericytes in GBM governs the ecology of the perivascular niche, but their function in mediating chemoresistance has not been fully explored. Herein, we uncovered that pericytes potentiate DNA damage repair (DDR) in GBM cells residing in the perivascular niche, which induces temozolomide (TMZ) chemoresistance. We found that increased pericyte proportion correlates with accelerated tumor recurrence and worse prognosis. Genetic depletion of pericytes in GBM xenografts enhances TMZ-induced cytotoxicity and prolongs survival of tumor-bearing mice. Mechanistically, C-C motif chemokine ligand 5 (CCL5) secreted by pericytes activates C-C motif chemokine receptor 5 (CCR5) on GBM cells to enable DNA-dependent protein kinase catalytic subunit (DNA-PKcs)-mediated DDR upon TMZ treatment. Disrupting CCL5-CCR5 paracrine signaling through the brain-penetrable CCR5 antagonist maraviroc (MVC) potently inhibits pericyte-promoted DDR and effectively improves the chemotherapeutic efficacy of TMZ. GBM patient-derived xenografts with high CCL5 expression benefit from combined treatment with TMZ and MVC. Our study reveals the role of pericytes as an extrinsic stimulator potentiating DDR signaling in GBM cells and suggests that targeting CCL5-CCR5 signaling could be an effective therapeutic strategy to improve chemotherapeutic efficacy against GBM.[/vc_column_text][vc_column_text]

Learn more:

The immunodeficient NCG mice (strain ID, T001475) were engrafted with human glioblastoma to generate patient-derived xenografts to study the effect of combined treatment of temozolomide (TMZ) and maraviroc (MVC)

Learn more about GemPharmatech’s immunodeficient mouse model, NCG, and its next generation NCG strains.

DOI:

doi:10.1038/s41422-021-00528-3[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

RELATED PRODUCTS

[/vc_column_text][vc_separator color=”custom” border_width=”2″ accent_color=”#004a80″][claue_addons_products limit=”4″ columns=”3″ issc=”1″ id=”77352″][/vc_column][/vc_row][vc_row][vc_column][vc_separator color=”custom” border_width=”2″ accent_color=”#004a80″][vc_btn title=”Back to Publications” style=”flat” color=”inverse” i_icon_fontawesome=”fas fa-caret-square-left” add_icon=”true” link=”url:https%3A%2F%2Fwww.atlantisbioscience.com.sg%2Fpublications%2F”][/vc_column][/vc_row]

CONTACT

QUESTIONS IN YOUR MIND?

Connect With Our Technical Specialist.

KNOW WHAT YOU WANT?

Request For A Quotation

DON'T MISS OUR.
FOLLOW US ON SOCIAL MEDIA!

OTHER BLOGS YOU MIGHT LIKE

HOW CAN WE HELP YOU? Our specialists are to help you find the best product for your application. We will be happy to help you find the right product for the job.

TALK TO A SPECIALIST

Contact our Customer Care, Sales & Scientific Assistance

EMAIL US

Consult and asked questions about our products & services

DOCUMENTATION

Documentation of Technical & Safety Data Sheet, Guides and more..